Trial Profile
Impact of Roflumilast on Visceral Adiposity and MetaBolic Profile in Chronic Obstructive Lung Disease: a Randomized and Controlled Trial: the RAMBO Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease; Metabolic syndrome
- Focus Pharmacodynamics
- Acronyms RAMBO
- 10 Nov 2014 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 17 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.